![Claire Poulard](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Claire Poulard
Direttore/Membro del Consiglio presso
Antabio SAS
Profilo
Claire Poulard is currently Director at Antabio SAS, Turenne Capital Partenaires SA, Newronika SRL, and AlgoTherapeutix SAS. At Omnes Capital SAS, the role started in 2015, with the title of Principal beginning in 2020, and currently holds the title of Partner.
Former roles include Director at Horama SA, AgomAb Therapeutics NV, and NH TherAguix SAS.
Posizioni attive di Claire Poulard
| Società | Posizione | Inizio |
|---|---|---|
Omnes Capital SAS /Venture/
 Omnes Capital SAS /Venture/ Investment ManagersFinance Omnes-Venture is an active manager which aims to combine an industrial and strategic overview of their target sectors with operational support for investee companies and financial optimization of investments. The firm takes minority stakes in recently founded businesses with strong European and international potential, focusing on the electronics, software, telecoms, life sciences and web technology services sectors. Their investment policy draws on exclusive sources of deal flow, including the management team's personal networks and privileged links to incubator funds, start-up funds, research labs, fundraisers and Crdit Agricole group's proprietary networks. They typically invest between 2 and 10 million euros. Omnes-Venture partners with investee companies, taking seats on supervisory boards or the board of directors, while respecting investee management's independence. They contribute to the company's strategy and development opportunities, select candidates for key positions in investee companies, working to optimize their financial resources and source industrial and financial partnerships. | Investitore di Private Equity | 12/04/2018 |
Antabio SAS
 Antabio SAS Pharmaceuticals: MajorHealth Technology Develops biopharmaceutical drugs | Direttore/Membro del Consiglio | - |
Newronika SRL
 Newronika SRL Medical SpecialtiesHealth Technology Manufactures medical and electro-medical equipment and appliances | Direttore/Membro del Consiglio | - |
Algotherapeutix SAS
 Algotherapeutix SAS Medical SpecialtiesHealth Technology Manufactures clinical supplies | Direttore/Membro del Consiglio | - |
Turenne Capital Partenaires SA
 Turenne Capital Partenaires SA Investment ManagersFinance Turenne Capital invests in small and middle market companies located in France. The firm focuses on healthcare, hospitality, environment, energetic transition and innovacom sectors. It participates in seed, early and later stage transactions with an investment size of less than EUR 30 million. | Direttore/Membro del Consiglio | - |
Omnes Capital SAS
 Omnes Capital SAS Investment ManagersFinance Omnes Capital invests in companies located in Europe and North America. The firm targets companies operating in the fields of energy transition, renewable energy, sustainable cities and deeptech. It participates in LBOs, MBO, buy-outs and growth equity investment. It also takes minority stakes. | Investitore di Private Equity | - |
Precedenti posizioni note di Claire Poulard
| Società | Posizione | Fine |
|---|---|---|
Horama SA
 Horama SA BiotechnologyHealth Technology Develops gene therapies for eye diseases | Direttore/Membro del Consiglio | - |
| NH THERAGUIX SAS | Direttore/Membro del Consiglio | - |
| AGOMAB THERAPEUTICS NV | Direttore/Membro del Consiglio | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
68
Relazioni di 1° grado
9
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 9 |
|---|---|
Turenne Capital Partenaires SA
Turenne Capital Partenaires SA Investment ManagersFinance Turenne Capital invests in small and middle market companies located in France. The firm focuses on healthcare, hospitality, environment, energetic transition and innovacom sectors. It participates in seed, early and later stage transactions with an investment size of less than EUR 30 million. | Finance |
Omnes Capital SAS
Omnes Capital SAS Investment ManagersFinance Omnes Capital invests in companies located in Europe and North America. The firm targets companies operating in the fields of energy transition, renewable energy, sustainable cities and deeptech. It participates in LBOs, MBO, buy-outs and growth equity investment. It also takes minority stakes. | Finance |
Omnes Capital SAS /Venture/
Omnes Capital SAS /Venture/ Investment ManagersFinance Omnes-Venture is an active manager which aims to combine an industrial and strategic overview of their target sectors with operational support for investee companies and financial optimization of investments. The firm takes minority stakes in recently founded businesses with strong European and international potential, focusing on the electronics, software, telecoms, life sciences and web technology services sectors. Their investment policy draws on exclusive sources of deal flow, including the management team's personal networks and privileged links to incubator funds, start-up funds, research labs, fundraisers and Crdit Agricole group's proprietary networks. They typically invest between 2 and 10 million euros. Omnes-Venture partners with investee companies, taking seats on supervisory boards or the board of directors, while respecting investee management's independence. They contribute to the company's strategy and development opportunities, select candidates for key positions in investee companies, working to optimize their financial resources and source industrial and financial partnerships. | Finance |
Antabio SAS
Antabio SAS Pharmaceuticals: MajorHealth Technology Develops biopharmaceutical drugs | Health Technology |
Newronika SRL
Newronika SRL Medical SpecialtiesHealth Technology Manufactures medical and electro-medical equipment and appliances | Health Technology |
Horama SA
Horama SA BiotechnologyHealth Technology Develops gene therapies for eye diseases | Health Technology |
AgomAb Therapeutics NV
 AgomAb Therapeutics NV BiotechnologyHealth Technology Develops molecular therapies for regeneration of damaged tissues | Health Technology |
NH TherAguix SAS
 NH TherAguix SAS Pharmaceuticals: MajorHealth Technology Operates as a clinical stage pharmaceutical company that develops nanomedicine for cancer, combining imaging and radiotherapy | Health Technology |
Algotherapeutix SAS
Algotherapeutix SAS Medical SpecialtiesHealth Technology Manufactures clinical supplies | Health Technology |
